Ardelyx, Inc.
ARDX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
ARDX Income Statement
ARDX Balance Sheet
ARDX Cash Flow
Recent trades of ARDX by members of U.S. Congress
ARDX Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
ARDX Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
ARDX Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ARDX's directors and management
Government lobbying spending instances
-
$720,000 Oct 16, 2024 Issue: Health Issues
-
$530,000 Jul 10, 2024 Issue: Health Issues
-
$530,000 Apr 02, 2024 Issue: Health Issues
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$80,000 Jan 21, 2024 Issue: Medicare/Medicaid
-
$60,000 Jan 20, 2024 Issue: Medicare/Medicaid Health Issues
-
$460,000 Oct 06, 2023 Issue: Medicare/Medicaid
-
$310,000 Jul 17, 2023 Issue: Medicare/Medicaid
-
$130,000 Jan 17, 2023 Issue: None
-
$50,000 Oct 20, 2022 Issue: Health Issues
-
$30,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$130,000 Jul 22, 2022 Issue: None
-
$130,000 Apr 20, 2022 Issue: None
-
$260,000 Jan 20, 2022 Issue: None
-
$240,000 Oct 20, 2021 Issue: None
-
$220,000 Jul 19, 2021 Issue: None
-
$190,000 Apr 19, 2021 Issue: None
-
$170,000 Jan 21, 2021 Issue: None
-
$30,000 Oct 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Apr 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 18, 2019 Issue: Medicare/Medicaid
-
$30,000 Jul 12, 2019 Issue: Medicare/Medicaid
-
$30,000 Apr 04, 2019 Issue: Medicare/Medicaid
-
$10,000 Jan 09, 2019 Issue: Medicare/Medicaid Health Issues
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Sep. 10, 2024
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Jun. 25, 2024
-
Patent Title: Glycyrrhetinic acid derivatives for use in treating hyperkalemia Jan. 02, 2024
-
Patent Title: Compounds and methods for inhibiting phosphate transport Nov. 14, 2023
-
Patent Title: Glycyrrhetinic acid derivatives for treating hyperkalemia Sep. 26, 2023
-
Patent Title: Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders Sep. 12, 2023
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 08, 2023
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders May. 03, 2022
-
Patent Title: Compounds useful for treating gastrointestinal tract disorders Feb. 08, 2022
-
Patent Title: Inhibitors of nhe-mediated antiport Oct. 19, 2021
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 17, 2021
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Apr. 06, 2021
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Mar. 09, 2021
-
Patent Title: Hormone receptor modulators for treating metabolic conditions and disorders Oct. 06, 2020
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Jan. 28, 2020
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Aug. 27, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 20, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 13, 2019
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Apr. 30, 2019
-
Patent Title: Compositions and methods for treating hyperkalemia Mar. 20, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia Jan. 16, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia May. 23, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 24, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 17, 2017
-
Patent Title: Compositions and methods for treating hyperkalemia Sep. 06, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Aug. 09, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Apr. 05, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 08, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Apr. 14, 2015
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Mar. 03, 2015
-
Patent Title: Compounds and methods for inhibiting phosphate transport Dec. 23, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 19, 2014
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Sep. 24, 2013
Government Contracts
Federal grants, loans, and purchases
- $12,100 2024-10-01 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-05-23 00:00:00 Agency: Department of Veterans Affairs
- $0 2024-04-29 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $0 2022-03-25 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of ARDX in WallStreetBets Daily Discussion
ARDX News
Recent insights relating to ARDX
CNBC Recommendations
Recent picks made for ARDX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ARDX
ARDX Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
ARDX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ARDX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More